Created in 2010, Boehringer Ingelheim Venture Fund invests in ground-breaking companies to drive innovation in biomedical research and patient care.
Portfolio
2
companies
Glox Therapeutics
Glox Therapeutics develops precision antibiotic therapies to combat antimicrobial resistance.
Brainomix
Brainomix develops artificial intelligence imaging software to assist clinicians in stroke and lung fibrosis care.
Oliver Reuss
Executive Director and Investment Manager
Niklas Czeloth
Executive Director / Investment Manager
The seed round was co-led by Boehringer Ingelheim Venture Fund and Scottish Enterprise to support laboratory establishment and team expansion.
"Our mission is to provide physicians and patients with highly potent, targeted antimicrobial therapies that can kill antibiotic-resistant bacteria for which there are diminishing options available for treatment,"
The financing round was co-led by Boehringer Ingelheim Venture Fund and Parkwalk Advisors, with participation from Tencent and Oxford University Innovation Fund.
"Over the past decade Brainomix has created the market for stroke AI imaging. As a spin-out from the University of Oxford it is an example of the UK's world-leading strengths in life sciences and AI-enabled medtech, combining expertise in clinical care and software development with more than 150 years' experience in the field across its leadership team."
